AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market
Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o
AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer
Xiamen, China, 19th February, 2021 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.
AmoyDx at WCLC 2020 wrap-up
As a supporter to WCLC 2020, AmoyDx set up a virtual booth with NSCLC product pipeline and sponsored an Industry Symposium with the hot topics of Biomarker Panel testing in Lung Cancer. Prof. Tony Mok (Chairmen), Prof. Koichi Goto and Prof. Caicun Zhou pr
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market
Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo
AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide
Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.
Visit AmoyDx at 2020 AMP Virtual Meeting & Expo
The 2020 AMP Virtual Meeting & Expo starts MONDAY and we cannot wait to meet you online. If you do not want to miss the great content shared from AmoyDx, be sure to stop by our virtual booth during November 16th - 20th.